Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to -$31.3 million.

  • Voyager Therapeutics' Free Cash Flow fell 1073.12% to -$31.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$118.9 million, marking a year-over-year decrease of 31468.84%. This contributed to the annual value of -$18.8 million for FY2024, which is 12522.13% down from last year.
  • Latest data reveals that Voyager Therapeutics reported Free Cash Flow of -$31.3 million as of Q3 2025, which was down 1073.12% from -$34.4 million recorded in Q2 2025.
  • Voyager Therapeutics' Free Cash Flow's 5-year high stood at $123.1 million during Q1 2023, with a 5-year trough of -$38.6 million in Q1 2025.
  • Its 5-year average for Free Cash Flow is -$6.2 million, with a median of -$21.4 million in 2021.
  • As far as peak fluctuations go, Voyager Therapeutics' Free Cash Flow surged by 25983.39% in 2023, and later crashed by 149154.03% in 2024.
  • Voyager Therapeutics' Free Cash Flow (Quarter) stood at $10.8 million in 2021, then plummeted by 221.47% to -$13.2 million in 2022, then crashed by 86.04% to -$24.5 million in 2023, then soared by 40.1% to -$14.7 million in 2024, then crashed by 112.85% to -$31.3 million in 2025.
  • Its Free Cash Flow was -$31.3 million in Q3 2025, compared to -$34.4 million in Q2 2025 and -$38.6 million in Q1 2025.